Avertto is stopping strokes before they start.

Up to 17% of strokes happen inside hospitals — in sedated, sleeping, or confused patients where no one can see the warning signs. By the time it's caught on rounds, clinical recognition typically takes 2–5 days.

AMIT301, our FDA Class I registered bedside monitor, catches the same event in the vascular phase — 30 to 60 minutes before it becomes a neurological one — while the patient is still treatable. In a blinded, multi-center clinical trial published in Stroke (2026), AMIT301 detected 100% of strokes in the study cohort.

At roughly $1,500 per patient monitored, the return to a hospital is 27x: a missed stroke can cost $140K–750K in downstream care, and recent malpractice verdicts for missed in-hospital stroke have reached $40M–75M.

We're live at Vall d'Hebron, Sheba, Galilee Medical Center, and Rabin, and building our U.S. cardiac ICU footprint — ISO 13485 certified, backed by the Israel Innovation Authority and the European Innovation Council.

Founded by Hilla Ben-Pazi, MD.

Avertto

Org chart

Teams

Offices

Avertto

Org chart

Teams

Offices

Related companies